Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843967 · ClinicalTrials.gov registry record · Phase 1
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
A Phase 1 study of Liposarcoma and Unresectable Dedifferentiated Liposarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 7
- Study locations
NCT06843967: Recruiting Phase 1 study of Liposarcoma and Unresectable Dedifferentiated Liposarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06843967 is a Phase 1 study of Liposarcoma and Unresectable Dedifferentiated Liposarcoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants, below the 80-participant average among 13 other Liposarcoma trials with a reported enrollment target (32% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06843967, a Phase 1 study of Liposarcoma and Unresectable Dedifferentiated Liposarcoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
Primary Outcome
To determine the recommended phase 2 dose (RP2D) of mirdametinib plus palbociclib in patients with DDLPS
Conditions Studied
Interventions
- DRUG Palbociclib
- DRUG Mirdametinib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2028-08-19 |
| Phase | Phase 1 |
What NCT06843967 shows while recruiting
NCT06843967 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 80-participant average among 13 other Liposarcoma trials with a reported enrollment target (32% lower).
The record links to 9 conditions, with Liposarcoma appearing as the primary indexed condition, and to 2 interventions - of which Palbociclib is the first listed.
NCT06843967 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06843967 about?
NCT06843967 is a clinical study titled "A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma". The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib t...
What is the current status of trial NCT06843967?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2025-02-19. Estimated completion is 2028-08-19.
What conditions does trial NCT06843967 study?
This clinical trial studies the following conditions: Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Myxoid Liposarcoma.
What interventions are being tested in trial NCT06843967?
The interventions under investigation include: Palbociclib (DRUG), Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT06843967?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843967 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liposarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06843967's enrollment target sits among peer trials
54 5th of 13 higher than 9 of 13 other Liposarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liposarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
RECRUITING · Phase 1
-
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI